Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study.
Shinnosuke TakemotoMinoru FukudaHiroyuki YamaguchiTakaya IkedaKazumasa AkagiHiromi TomonoYasuhiro UmeyamaYosuke DotsuHirokazu TaniguchiHiroshi GyotokuHiroaki SenjuTakeshi KitazakiKatsumi NakatomiSeiji NagashimaMasaaki FukudaAkitoshi KinoshitaHiroshi SodaHiroshi MukaePublished in: Thoracic cancer (2019)
A previous study indicated that administering chemotherapy in combination with bevacizumab was effective at controlling pleural effusion in patients with NSCLC with carcinomatous pleurisy. It is expected that ramucirumab will have a similar effect to the same group.